{"version":"1.0","type":"link","title":"Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.","author_name":"Capdevila J 외","author_url":"https://prs-insight.online/author/Capdevila%20J","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/138997","thumbnail_width":1200,"thumbnail_height":630}